Key Insights on Gross Profit: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.

Biotech Giants: Gilead vs. Regeneron Gross Profit Trends

__timestampGilead Sciences, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014211020000002614539000
Thursday, January 1, 2015286330000003711019000
Friday, January 1, 2016261290000004560733000
Sunday, January 1, 2017217360000005475166000
Monday, January 1, 2018172740000006276700000
Tuesday, January 1, 2019177740000007081200000
Wednesday, January 1, 2020201170000007377200000
Friday, January 1, 20212070400000013634200000
Saturday, January 1, 20222162400000010612500000
Sunday, January 1, 20232061800000011301400000
Monday, January 1, 20247820000012231500000
Loading chart...

Unleashing insights

A Decade of Gross Profit Trends: Gilead Sciences vs. Regeneron Pharmaceuticals

In the ever-evolving landscape of biotechnology, Gilead Sciences, Inc. and Regeneron Pharmaceuticals, Inc. have emerged as key players. Over the past decade, from 2014 to 2023, these companies have demonstrated contrasting trajectories in gross profit. Gilead Sciences, once a leader with a peak gross profit in 2015, has seen a gradual decline, with a 28% drop by 2023. In contrast, Regeneron Pharmaceuticals has experienced a remarkable growth, with its gross profit surging by over 330% during the same period. This shift highlights Regeneron's strategic advancements and market adaptability, positioning it as a formidable competitor. As the biotech industry continues to innovate, these trends underscore the dynamic nature of financial performance and the importance of strategic foresight.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025